What’s newsworthy in the Trenton, N.J., and surrounding areas.
—New 103,720 ft2 Facility to Serve as Headquarters and House 150 Employees in Cranbury, NJ— —State of the Art R&D Facility to Support Manufacturing Including AAV Drug Product— —cGMP Production to be Initiated in 2021 for Planned Phase 2 Study of First
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies remains under review
PRINCETON, N.J.–(BUSINESS WIRE)–Energy cost savings topped the list for customer needs when considering distributed energy resources (DER) in a recent study by NRG Energy, Inc. (NSYE: NRG) in collaboration with Smart Energy Decisions (SED). The goal of the State of Distributed Energy
Marketing Authorization Application is supported by positive results from the pivotal Phase 3 True North study evaluating oral Zeposia (ozanimod) in adults with moderately to severely active ulcerative colitis If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for
PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus placebo plus
Reeling from the pandemic, transit agencies are grappling with drastic reductions in ridership and pleading for help from Washington. — NYT: Top Stories
First immunotherapy to be approved for a gastroesophageal cancer in the European Union Approval based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today
Dustin Johnson’s final round lead is narrowing as his playing partner, Sungjae Im, applies pressure. — NYT: Top Stories